
Healthy male or females patients, 18 years and older, who have a localized area of abdominal subcutaneous fat
 Patients who have satisfactory abdominal elasticity as assessed by Doctor

Have a history of stable diet and exercise routine in the 3 months prior to screening and have a body mass index (BMI) less than 25
To check your BMI hold down the Ctrl key and click the following link http://www.nhlbisupport.com/bmi/

Female subjects who agree to use adequate birth control methods (abstinence, stabilized oral contraceptives, implant, injections, IUD, Patch, NuvaRing®, condoms etc.) throughout the entire study until completion

History of prior treatment of abdominal subcutaneous adipose tissue (i.e. abdominoplasty, liposuction, exposure to ablative or body contouring devices, mesotherapy or lipolytic agents)

Female subjects who are within 12 months post-partum, who are pregnant, lactating, and/or who are of childbearing potential
 Any skin conditions in the treatment area (i.e. skin infections, psoriasis, eczema, tattoos, striae, keloids, excessive skin wrinkles, pannus or tethered scars
 Subjects planning to embark on a weight loss or exercise program during the study
 Subjects who partake of abdominal massaging and who are unwilling to discontinue this therapy during the study

Enrollment in another investigational drug or device study; or use of any experiment al or investigational drug or device within 30 days

Subjects unlikely or unable to comply with protocol procedures or adhere to the study visit schedule